Cargando…
Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis
BACKGROUND: Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial. METHODS: We have performed a national retrospective, nonexperimental comparative study from two tertiary ho...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101788/ https://www.ncbi.nlm.nih.gov/pubmed/34088524 http://dx.doi.org/10.1016/j.medcli.2021.04.005 |
_version_ | 1783689017079889920 |
---|---|
author | Aparisi, Álvaro Catalá, Pablo Amat-Santos, Ignacio J. Marcos-Mangas, Marta López-Otero, Diego Veras, Carlos López-Pais, Javier Cabezón-Villalba, Gonzalo Cacho Antonio, Carla Eugenia Candela, Jordi Antúnez-Muiños, Pablo Gil, José Francisco González Ferrero, Teba Rojas, Gino Pérez-Poza, Marta Uribarri, Aitor Otero-García, Oscar García-Granja, Pablo Elpidio Jiménez Ramos, Víctor Revilla, Ana Dueñas, Carlos Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto |
author_facet | Aparisi, Álvaro Catalá, Pablo Amat-Santos, Ignacio J. Marcos-Mangas, Marta López-Otero, Diego Veras, Carlos López-Pais, Javier Cabezón-Villalba, Gonzalo Cacho Antonio, Carla Eugenia Candela, Jordi Antúnez-Muiños, Pablo Gil, José Francisco González Ferrero, Teba Rojas, Gino Pérez-Poza, Marta Uribarri, Aitor Otero-García, Oscar García-Granja, Pablo Elpidio Jiménez Ramos, Víctor Revilla, Ana Dueñas, Carlos Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto |
author_sort | Aparisi, Álvaro |
collection | PubMed |
description | BACKGROUND: Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial. METHODS: We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings. RESULTS: Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19. CONCLUSION: Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes. |
format | Online Article Text |
id | pubmed-8101788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81017882021-05-07 Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis Aparisi, Álvaro Catalá, Pablo Amat-Santos, Ignacio J. Marcos-Mangas, Marta López-Otero, Diego Veras, Carlos López-Pais, Javier Cabezón-Villalba, Gonzalo Cacho Antonio, Carla Eugenia Candela, Jordi Antúnez-Muiños, Pablo Gil, José Francisco González Ferrero, Teba Rojas, Gino Pérez-Poza, Marta Uribarri, Aitor Otero-García, Oscar García-Granja, Pablo Elpidio Jiménez Ramos, Víctor Revilla, Ana Dueñas, Carlos Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto Med Clin (Barc) Original Article BACKGROUND: Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin–angiotensin–aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial. METHODS: We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings. RESULTS: Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (−0.151 [95% CI −0.218, −0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (−0.167 [95% CI −0.220, −0.114]) and during hospitalization (0.090 [−0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224–0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42–0.8]) among hypertensive COVID-19. CONCLUSION: Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes. Elsevier España, S.L.U. 2022-04-08 2021-05-06 /pmc/articles/PMC8101788/ /pubmed/34088524 http://dx.doi.org/10.1016/j.medcli.2021.04.005 Text en © 2021 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Aparisi, Álvaro Catalá, Pablo Amat-Santos, Ignacio J. Marcos-Mangas, Marta López-Otero, Diego Veras, Carlos López-Pais, Javier Cabezón-Villalba, Gonzalo Cacho Antonio, Carla Eugenia Candela, Jordi Antúnez-Muiños, Pablo Gil, José Francisco González Ferrero, Teba Rojas, Gino Pérez-Poza, Marta Uribarri, Aitor Otero-García, Oscar García-Granja, Pablo Elpidio Jiménez Ramos, Víctor Revilla, Ana Dueñas, Carlos Gómez, Itzíar González-Juanatey, José Ramón San Román, J. Alberto Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title_full | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title_fullStr | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title_full_unstemmed | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title_short | Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis |
title_sort | chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive covid-19 patients: results from a spanish registry and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101788/ https://www.ncbi.nlm.nih.gov/pubmed/34088524 http://dx.doi.org/10.1016/j.medcli.2021.04.005 |
work_keys_str_mv | AT aparisialvaro chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT catalapablo chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT amatsantosignacioj chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT marcosmangasmarta chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT lopezoterodiego chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT verascarlos chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT lopezpaisjavier chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT cabezonvillalbagonzalo chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT cachoantoniocarlaeugenia chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT candelajordi chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT antunezmuinospablo chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT giljosefrancisco chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT gonzalezferreroteba chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT rojasgino chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT perezpozamarta chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT uribarriaitor chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT oterogarciaoscar chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT garciagranjapabloelpidio chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT jimenezramosvictor chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT revillaana chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT duenascarlos chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT gomezitziar chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT gonzalezjuanateyjoseramon chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis AT sanromanjalberto chronicuseofreninangiotensinaldosteroneinhibitorsinhypertensivecovid19patientsresultsfromaspanishregistryandmetaanalysis |